General Pharmacology Practice Questions

Q: All of the following are true regarding Phase II clinical trials, except:

They are conducted in patients with the target disease.. **Explanation:** The correct answer is **B** because the statement "They are conducted in patients with the target disease" is actually a **true** characteristic of Phase II trials. In the context of an "except" question, the provided key suggests a potential error in the question's framing or the options provided, as Option D is the most scientifically inaccurate statement. **1. Why Option D is the correct "Except" (The False Statement):** Phase I trials are primarily designed to assess **safety, tolerability, and pharmacokinetics** in healthy volunteers. They are **not** designed to establish efficacy. Therefore, "positive evidence of efficacy" cannot be a prerequisite from Phase I, as efficacy is first explored in Phase II. **2. Analysis of Other Options:** * **Option A (True):** Phase II is the first time the drug is tested for **efficacy** (does it work?) while continuing to monitor **safety** in a larger group than Phase I. * **Option B (True):** Unlike Phase I (healthy volunteers), Phase II trials are conducted in a small group (100–300) of **patients** who actually have the target disease. * **Option C (True):** Phase II trials are officially designated as **Therapeutic Exploratory** trials because they aim to determine the therapeutic dose range and initial clinical effect. **High-Yield Clinical Pearls for NEET-PG:** * **Phase I:** Safety & Pharmacokinetics (Healthy volunteers; "Human Pharmacology"). * **Phase II:** Efficacy & Dose-ranging (Small patient group; "Therapeutic Exploratory"). * **Phase III:** Confirmation of efficacy & safety (Large multicentric patient group; "Therapeutic Confirmatory"). * **Phase IV:** Post-marketing surveillance (Detects rare/long-term adverse effects). * **Phase 0:** Microdosing trials to study pharmacokinetics (Sub-therapeutic doses).

Q: Which of the following drugs is used as a diagnostic tool?

Tensilon. **Explanation:** **Tensilon (Edrophonium)** is the correct answer because it is a very short-acting acetylcholinesterase inhibitor. Historically, it was the drug of choice for the **Tensilon Test** used to diagnose **Myasthenia Gravis (MG)**. Due to its rapid onset (30–60 seconds) and brief duration of action (5–10 minutes), it provides a quick window to observe the transient improvement of muscle weakness (e.g., ptosis) in MG patients. While bedside ice-pack tests and antibody titers have largely replaced it, it remains a classic diagnostic tool in pharmacological literature. **Analysis of Incorrect Options:** * **Cevimeline:** A cholinergic agonist (M1/M3 selective) used **therapeutically** to treat xerostomia (dry mouth) in Sjögren’s syndrome, not for diagnosis. * **Vedolizumab:** A monoclonal antibody (integrin receptor antagonist) used for the **treatment** of inflammatory bowel diseases like Crohn’s disease and Ulcerative Colitis. * **Sacubitril:** A neprilysin inhibitor used in **combination with Valsartan (ARNI)** for the management of chronic heart failure with reduced ejection fraction. **Clinical Pearls for NEET-PG:** * **Tensilon Test:** Improvement in strength indicates Myasthenia Gravis; worsening of strength indicates a **Cholinergic Crisis** (overdose of AChE inhibitors). * **Antidote:** Atropine should always be kept ready during a Tensilon test to manage potential bradycardia or excessive salivation. * **Current Gold Standard:** For MG diagnosis, **Anti-AChR antibody** testing is the most specific, while **Single-fiber EMG** is the most sensitive.

Q: Which of the following statements about fexofenadine is true?

It does not block cardiac K+ channels.. ### Explanation **Correct Answer: C. It does not block cardiac K+ channels.** **1. Why the Correct Answer is Right:** Fexofenadine is a second-generation H1 antihistamine. Its predecessor, **Terfenadine**, was notorious for blocking delayed rectifier potassium ($K^+$) channels in the heart, leading to QT interval prolongation and a life-threatening arrhythmia known as *Torsades de Pointes*. Fexofenadine, the active metabolite of terfenadine, retains the antihistaminic efficacy but **lacks the $K^+$ channel-blocking property**, making it cardiosafe. **2. Analysis of Incorrect Options:** * **Option A:** Fexofenadine does not undergo significant hepatic metabolism. It is primarily excreted unchanged in the feces and urine. * **Option B:** This is reversed. **Fexofenadine is the active metabolite of Terfenadine.** Terfenadine is a prodrug that is converted to fexofenadine by the CYP3A4 enzyme. * **Option D:** Fexofenadine is a second-generation antihistamine with **low lipid solubility** and is a substrate for the P-glycoprotein efflux pump. Consequently, it does not cross the blood-brain barrier effectively and has a **very low affinity for central H1 receptors**, making it non-sedating. **3. High-Yield Clinical Pearls for NEET-PG:** * **"The Safe Metabolite":** Fexofenadine was developed to avoid the drug-drug interactions seen with Terfenadine (e.g., when taken with Ketoconazole or Erythromycin, which inhibit CYP3A4, leading to toxic Terfenadine levels). * **Non-Sedating Profile:** Along with Loratadine and Cetirizine, Fexofenadine is preferred for patients in occupations requiring high alertness (e.g., pilots, drivers). * **Interaction:** Avoid taking fexofenadine with fruit juices (orange, grapefruit, apple) as they inhibit OATP1A2, reducing the drug's absorption.

Q: In which phase of clinical trials are micro-dosing studies typically conducted?

Phase 0. **Explanation:** **Phase 0** (also known as **Human Micro-dosing studies**) is the correct answer. These trials are conducted very early in the drug development process, often before traditional Phase 1 trials. The primary objective is to evaluate the **pharmacokinetics (PK) and pharmacodynamics (PD)** of a drug candidate in humans using sub-therapeutic doses (usually 1/100th of the calculated pharmacological dose). This helps researchers decide whether a drug should proceed to full-scale clinical development, thereby saving time and resources. **Why other options are incorrect:** * **Phase 1:** These are the first-in-human trials using therapeutic (escalating) doses. The primary goal is to determine **safety, tolerability, and the Maximum Tolerated Dose (MTD)** in a small group of healthy volunteers (except for oncology drugs). * **Phase 2:** These are "Proof of Concept" trials conducted on a small group of **patients** (100–300) to evaluate **efficacy** and determine the optimal dose range. * **Phase 3:** These are large-scale, multicentric, randomized controlled trials (RCTs) conducted on thousands of patients to confirm efficacy and compare the new drug against the current **standard of care**. **High-Yield Pearls for NEET-PG:** * **Phase 0** was introduced by the USFDA (2006) under the "Exploratory IND" (Investigational New Drug) guidance. * **Sample Size:** Very small (usually 10–15 subjects). * **Tool Used:** Highly sensitive analytical techniques like **Accelerator Mass Spectrometry (AMS)** are used to detect the minute concentrations of the drug in the blood. * **Phase 4:** Also known as **Post-Marketing Surveillance**, it is used to detect rare long-term adverse effects (e.g., Phocomelia with Thalidomide).

Q: Variation in the sensitivity of a population of individuals to increasing doses of a drug is best determined by which of the following?

Quantal dose-response. **Explanation:** The correct answer is **Quantal dose-response**. **1. Why Quantal Dose-Response is Correct:** A **Quantal dose-response curve** describes an "all-or-none" response (e.g., sleep vs. awake, alive vs. dead, relief of headache vs. no relief). Unlike a graded dose-response curve, which measures the intensity of effect in a single individual, the quantal curve plots the **cumulative frequency of individuals** in a population who exhibit a specific effect at increasing doses. Therefore, it is the primary tool used to determine **population variability** and sensitivity to a drug. **2. Why Other Options are Incorrect:** * **Efficacy (A):** Refers to the maximum effect ($E_{max}$) a drug can produce, regardless of dose. It relates to the drug's intrinsic activity, not population sensitivity. * **Potency (B):** Refers to the amount of drug (dose) required to produce an effect of a given intensity (usually measured as $EC_{50}$). While it compares drugs, it does not inherently measure population-wide sensitivity variation. * **Therapeutic Index (C):** This is a ratio ($TD_{50} / ED_{50}$) derived from quantal dose-response curves to measure drug safety. While it uses population data, it describes the safety margin rather than the variation in sensitivity itself. **High-Yield NEET-PG Pearls:** * **Graded Dose-Response:** Measures the *magnitude* of effect in an individual (determines $E_{max}$ and $EC_{50}$). * **Quantal Dose-Response:** Measures the *frequency* of effect in a population (determines $ED_{50}$, $TD_{50}$, and $LD_{50}$). * **Slope of Quantal Curve:** A steep slope indicates that most of the population responds within a narrow dose range (low variability), whereas a shallow slope indicates high individual variation in drug sensitivity.

Q: Which of the following is an example of a covalent drug-receptor interaction?

Phenoxybenzamine binding to the alpha adrenergic receptor. **Explanation:** The correct answer is **D. Phenoxybenzamine binding to the alpha adrenergic receptor.** **1. Why Phenoxybenzamine is Correct:** Most drug-receptor interactions are mediated by weak, reversible bonds (e.g., ionic, hydrogen, or Van der Waals). However, **Phenoxybenzamine** is a classic example of an **irreversible, non-competitive antagonist**. It undergoes a chemical transformation to form a highly reactive ethyleniminium intermediate, which then forms a **strong covalent bond** with the alpha-adrenergic receptor. Because covalent bonds are extremely stable, the blockade cannot be overcome by increasing the concentration of the agonist (like Noradrenaline). The effect lasts for 24–48 hours, as the body must synthesize new receptors to restore function. **2. Why the Other Options are Incorrect:** * **Options A & B (Noradrenaline and Acetylcholine):** These are endogenous neurotransmitters. Physiological signaling requires rapid onset and termination; therefore, these ligands bind via **reversible** (non-covalent) bonds to allow for quick dissociation. * **Option C (Prazosin):** Unlike phenoxybenzamine, Prazosin is a **selective, competitive** alpha-1 blocker. It binds via reversible ionic or hydrogen bonds, meaning its inhibitory effect can be reversed by increasing the concentration of an agonist. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other Covalent/Irreversible Drugs:** Aspirin (COX inhibition), Omeprazole (Proton pump inhibition), Organophosphates (AChE inhibition), and Vigabatrin (GABA-transaminase inhibition). * **Clinical Use:** Phenoxybenzamine is primarily used in the preoperative management of **Pheochromocytoma** to prevent hypertensive crises. * **Key Concept:** Irreversible antagonists reduce the **Emax** (maximal efficacy) of an agonist on a dose-response curve, rather than just shifting the EC50.

Q: In which phase of clinical trials are healthy human volunteers typically included?

Phase I. **Explanation:** **Phase I Clinical Trials** are primarily designed to assess the **safety, tolerability, and pharmacokinetics** of a new drug. This phase typically involves a small group (20–80) of **healthy human volunteers**. The goal is to determine the Maximum Tolerated Dose (MTD) and establish the safety profile before testing the drug in patients. *Exception:* In cases of highly toxic drugs (e.g., Cytotoxic Anticancer drugs), Phase I is conducted directly on patients rather than healthy volunteers. **Why other options are incorrect:** * **Phase II (Therapeutic Exploratory):** This phase is conducted on a small group of **actual patients** (100–300) to evaluate **efficacy** and determine the optimal dose-range. * **Phase III (Therapeutic Confirmatory):** This involves a large multicentric study on **patients** (1,000–3,000) to confirm efficacy and safety compared to the existing standard of care or placebo. * **Phase IV (Post-Marketing Surveillance):** This occurs **after** the drug is approved and marketed. It monitors long-term safety and identifies rare adverse effects in the general population. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0 (Microdosing):** Uses sub-therapeutic doses in humans to study pharmacokinetics; it precedes Phase I. * **"Human Pharmacology"** is another name for Phase I. * **Phase II** is the first phase where **efficacy** is measured (Proof of Concept). * **Phase III** is the most expensive and time-consuming phase. * **Teratogenicity** and rare side effects are usually detected in **Phase IV**.

Q: Which of the following drugs is not converted into an active metabolite?

Lisinopril. The correct answer is **Lisinopril**. **1. Why Lisinopril is correct:** Most ACE inhibitors (like Enalapril, Ramipril, and Perindopril) are **prodrugs** [2], meaning they are inactive in their parent form and must be converted by hepatic esterases into their active “–at” forms (e.g., Enalaprilat). However, **Lisinopril** and **Captopril** are the two notable exceptions; they are active in their parent form and do not require hepatic metabolism for activation [1]. This makes Lisinopril particularly useful in patients with liver dysfunction. **2. Why the other options are incorrect:** * **Fluoxetine:** This SSRI is metabolized in the liver to **Norfluoxetine**, which is a potent active metabolite with a significantly longer half-life than the parent drug. * **Cyclophosphamide:** This is a classic **prodrug**. It is inactive until it is metabolized by hepatic cytochrome P450 enzymes (specifically CYP2B6) into active metabolites like **phosphoramide mustard** (the alkylating agent) and acrolein (the metabolite responsible for hemorrhagic cystitis). * **Diazepam:** This benzodiazepine has several long-acting active metabolites, including **Desmethyldiazepam (Nordiazepam)**, Oxazepam, and Temazepam, which contribute to its prolonged duration of action. **3. High-Yield NEET-PG Clinical Pearls:** * **ACE Inhibitor Exceptions:** Remember the mnemonic: *“All ACE inhibitors are prodrugs except **C**aptopril and **L**isinopril”* (**C**an **L**ive). * **Lisinopril Excretion:** Since it is not metabolized by the liver, it is excreted unchanged by the kidneys. Dose adjustment is crucial in renal failure. * **Prodrugs to remember:** Levopa (to Dopamine), Terfenadine (to Fexofenadine), and Clopidogrel (activated by CYP2C19).

Question 1

All of the following are true regarding Phase II clinical trials, except:

Accepted Answer

They are conducted in patients with the target disease.

Answer

They assess safety and efficacy.

Answer

They are considered therapeutic exploratory trials.

Answer

Positive evidence of efficacy from Phase I trials is a prerequisite.

Question 2

Which of the following drugs is used as a diagnostic tool?

Accepted Answer

Tensilon

Answer

Cevimeline

Answer

Vedolizumab

Answer

Sacubitril

Question 3

What is true about tachyphylaxis?

Accepted Answer

Indirect sympathomimetics involved

Answer

Direct sympathomimetic involved

Answer

Mechanism clearly understood

Answer

Ephedrine tachyphylaxis reversed with noradrenaline

Question 4

Which of the following statements about fexofenadine is true?

Accepted Answer

It does not block cardiac K+ channels.

Answer

It undergoes high first-pass metabolism in the liver.

Answer

Terfenadine is an active metabolite of this drug.

Answer

It has high affinity for central H1 receptors.

Question 5

In which phase of clinical trials are micro-dosing studies typically conducted?

Accepted Answer

Phase 0

Answer

Phase 1

Answer

Phase 2

Answer

Phase 3

Question 6

Variation in the sensitivity of a population of individuals to increasing doses of a drug is best determined by which of the following?

Accepted Answer

Quantal dose-response

Answer

Efficacy

Answer

Potency

Answer

Therapeutic index

Question 7

Which of the following is an example of a covalent drug-receptor interaction?

Accepted Answer

Phenoxybenzamine binding to the alpha adrenergic receptor

Answer

Noradrenaline binding to the β1 adrenergic receptor

Answer

Acetylcholine binding to the muscarinic receptor

Answer

Prazosin binding to the α1 adrenergic receptor

Question 8

Which of the following statements is true regarding the intravenous route of drug administration?

Accepted Answer

Suspensions can be administered

Answer

It is useful in emergencies

Answer

Aseptic precautions are required

Answer

Bioavailability is 100%

Question 9

In which phase of clinical trials are healthy human volunteers typically included?

Accepted Answer

Phase I

Answer

Phase II

Answer

Phase III

Answer

Phase IV

Question 10

Which of the following drugs is not converted into an active metabolite?

Accepted Answer

Lisinopril

Answer

Fluoxetine

Answer

Cyclophosphamide

Answer

Diazepam

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?